通讯员 于龙 李亚宁 近日，山东省发展和改革委员会公布《2025年新认定（第32批）山东省企业技术中心名单》，山东蓬勃 生物科技有限公司凭借过硬的研发实力与创新能力成功入选，标志着该公司科技创新平台建设迈入新阶 段。 据了解，山东省企业技术中心是山东省创新体系的重要组成部分，需承担制定企业创新规划、凝聚高层 次科研人才、实施技术研发项目、构建自主知识产权体系等核心任务，是衡量企业技术创新水平的重要 标杆。此次获批，是主管部门对山东蓬勃生物研发体系完整性、技术创新能力及行业贡献度的高度认 可，为该公司持续引领行业技术发展筑牢基础。 山东蓬勃生物成立于2014年，是集研发、生产、销售于一体的国家级高新技术企业、山东省"专精特 新"中小企业，核心业务聚焦内生菌源农用新化合物创制，服务全球农药、肥料领域龙头企业。该公司 长期深耕技术创新，近5年平均研发投入强度超20%，拥有4000㎡研发中心，已组建山东省"一企一技 术"研发中心、山东省博士后创新实践基地等8个省市级科研平台。 依托"野生植物与内生真菌互惠共生"理论，该公司构建起国际领先的内生菌源超高活性农用新化合物研 发体系，年均筛选十余个新型农用化合物（多个为国际 ...

Group 1 - Shaanxi Guotou A has received acceptance for its application to issue A-shares to specific targets, pending further review and approval by the Shenzhen Stock Exchange and the China Securities Regulatory Commission [1] - *ST Dongtong has received a notice of termination of stock listing due to false disclosures in annual reports from 2019 to 2022, leading to a suspension of trading [2] - Jianlong Micro-Nano has terminated its major asset restructuring plan, concluding that the conditions for implementation are not mature [3] Group 2 - China Iron & Steel Logistics Group plans to increase its stake in China Iron & Steel by investing between 65 million and 130 million yuan within six months [4] - Industrial Fulian has adjusted its share repurchase price ceiling to no more than 75 yuan per share, up from a previous limit of 19.36 yuan [5] - Fujian Expressway intends to invest 180 million yuan in a capital increase project for Haixia Insurance, acquiring an 18% stake [6] Group 3 - Beixin Building Materials plans to use up to 8 billion yuan of idle funds for entrusted wealth management, aiming for capital preservation and appreciation [8] - Mao Ye Commercial has confirmed that its production and operation are normal despite recent stock price fluctuations [10] - Sanjiang Shopping has reported a significantly higher rolling P/E ratio of 70.45 compared to the industry average of 26.11 [11] Group 4 - Pinming Technology has experienced a stock price increase of 255.54% from September 25 to November 26, leading to potential trading risks [13] - Jiangbolong's vice president plans to reduce his stake by up to 30,600 shares, representing 0.0073% of the total share capital [15] - He Sheng Co. shareholders plan to collectively reduce their stake by up to 3% [16] Group 5 - Baiao Chemical's major shareholders plan to transfer a total of 10% of the company's shares, with a total consideration of approximately 1.986 billion yuan [18] - *ST Huawang's subsidiary plans to invest 10 million yuan to establish a wholly-owned subsidiary in Yibin, Sichuan [19] - *ST Yatai's restructuring application has been accepted by the court, leading to a risk warning for its stock [20]

Group 1: Pharmaceutical Business Development - The company’s pharmaceutical business is rapidly developing, focusing on a major client strategy and CDMO business model, with partnerships established with several leading global pharmaceutical companies [1] - The pharmaceutical division has formed stable commercial relationships with a number of high-quality domestic and international clients, leading to an expansion of the business coverage and deepening cooperation [1] - Future growth in the pharmaceutical sector is anticipated as the company continues to promote products during clients' patent periods [1] Group 2: Research and Development Expansion - The company is expanding its R&D efforts into new areas, including small molecule CDMO, starting materials, GMP intermediates, and advanced raw materials [2] - New directions in R&D include amino acids, peptides, PROTAC/ADC linkers, and oligonucleotides, with a focus on providing diverse linker synthesis services for ADC/PROTAC drug development [2] - These initiatives are expected to broaden the service scope of the pharmaceutical CDMO business and enable the company to undertake more projects [2] Group 3: Key Product Updates - The company continues to provide advanced intermediates K amine for chlorantraniliprole under a long-term partnership with a client, with a stable pricing model based on cost-plus [3] - The company adheres to a long-term contract strategy, ensuring trust and integrity in client relationships [3] Group 4: New Energy Sector Outlook - The company primarily sells LiFSI and electrolyte products, with ongoing technical improvements in lithium hexafluorophosphate projects [4] - Revenue from the new energy business is expected to break through in 2025, with a focus on large client strategies and enhancing production capabilities [4] Group 5: Agricultural Protection Business - The agricultural protection industry is highly concentrated, with the company engaging in CDMO business driven by technological innovation and establishing long-term strategic partnerships with multiple international agricultural companies [6] - The company has multiple production bases in China and overseas, including a new base in Malaysia to meet supply chain needs [6] - The company aims to provide differentiated, one-stop supply chain solutions leveraging its comprehensive chemical supply chain in China and flexible production policies in the UK and Malaysia [6]

证券日报网讯 利民股份11月26日在互动平台回答投资者提问时表示，公司产品价格变动主要系供需关 系影响。公司杀菌剂如代森锰锌和百菌清等产品由于需求端旺盛，2025年产品价格持续上涨；阿维菌素 等产品在四季度处于淡季，需求下降导致价格下跌，后续价格预计会周期性反弹。对公司业绩的影响除 了考虑价格变动之外，还需考虑体量以及成本等多种因素。综合考虑价格、成本、体量等因素来看，代 森锰锌和百菌清对业绩的影响会更大。 （编辑 袁冠琳） ...

证券日报网讯长青股份（002391）11月26日在互动平台回答投资者提问时表示，公司功夫菊酯及联苯菊 酯的产品价格稳定。 ...

Group 1 - The core viewpoint of the article is that Noposion (SZ 002215) announced an investor survey scheduled for November 26, 2025, where the company’s board secretary will address investor questions [1] - For the first half of 2025, Noposion's revenue composition is as follows: 49.42% from the industrial chain business, 40.45% from pesticide formulation business, and 10.13% from the Tiantian Circle business [1] - As of the time of reporting, Noposion's market capitalization is 10.8 billion yuan [1]

Group 1 - The core viewpoint of the article is that the price changes of the company's products are primarily influenced by supply and demand dynamics, with significant price increases for key products like Mancozeb and Chlorothalonil, while prices for products like Abamectin are expected to rebound after a seasonal decline [2][3] - The company indicated that the strong demand for its fungicides, such as Mancozeb and Chlorothalonil, is expected to lead to sustained price increases through 2025 [2] - The impact on the company's performance is influenced not only by price changes but also by factors such as volume and costs, with Mancozeb and Chlorothalonil expected to have a greater overall impact on performance compared to Abamectin [2]

Group 1 - The company, Limin Co., Ltd. (002734.SZ), reported that its current production and operational status is normal [2] - The pesticide industry is transitioning from off-peak to peak season, with demand gradually recovering [2] - The company anticipates that pesticide prices will stabilize and rebound in the near future [2]

利民股份（002734.SZ）11月26日在投资者互动平台表示，公司代森锰锌产能为45000吨/年，处于满产 满销状态；公司持有新河公司34%的股份，新河公司百菌清产能为30000吨/年，处于满产满销状态。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：公司拳头产品代森锰锌和百菌清，最新的产能是多 少？目前产能利用率怎么样？ ...

（记者 胡玲） 长青股份（002391.SZ）11月26日在投资者互动平台表示，目前公司年产2000吨功夫菊酯装置生产负荷 约为50%，年产1000吨联苯菊酯装置为满负荷生产。 每经AI快讯，有投资者在投资者互动平台提问：公司功夫菊酯、联苯菊酯产品超能利用率如何？ ...